Incidence and risk factors for chylothorax after pediatric heart surgeries: retrospective analysis of a large institution database​

Background: Risk factors for postoperative chylothorax in children who had cardiothoracic procedures are not always clear. Due to complex course in post-operative care, It's always challenging to find the risk factors, and their management. Objective: The aim of our study was to identify the incidence, risk factors and effective treatment approaches for chylothorax after pediatric heart surgery. Methods: Children who had the cardiac surgery and subsequently developed chylothorax were included in the study. The ratio of the experimental group to the control groupwas 1:2. Decannulations of extracorporeal membrane oxygenation (ECMO)were not included in the analysis of patient outcomes. For each patient, we keep track of their age, weight, gender, syndrome, RACH-1 scoring, fluid balance, bypass time, clamp time, redo operations, open or close heart surgeries, and rhythmdifficulties. Care logswere kept for every single therapy that was administered. Primary outcomewas chylothorax, with secondary outcomes included time in the intensive care unit (ICU), length of hospital stay (LOS), and death. Results: 5210 surgeries were performed in six years. 96 patients developed the chylothorax with incidence of 1.8%. In chylothorax group, mean weight was 6.7 ± 4.2, while mean age was 11.7 ± 15.2. Clamp time was 74.5 ± 53.5 versus 39.9± 13.7.Mean bypass timewas 128.34(76.25) versus 84.3± 25.1 with an odds ratio 1.02 (Z test 0.0001). Six (6.3%) children with chylothorax had redo cardiac surgeries in the same admission (p-value 0.01) while none in other. Five (5.2%) cases got operated by thoracotomy, three from left side.MeanChest tube durationwas 10± 7.8 days versus 3.8± 2.4 in control group. (p-value 0.02). chylothorax resolved (mean resolving time 1⁄4 4 days) in 76 (79.2%) children with monogen formula. Two patients receive midodrine with no significant effect. Four children underwent surgical repair for chylothorax. Conclusion: Bypass time linearly increasesincidence of chylothorax. Younger age, low weight, syndromic children, redo operations, non-open-heart surgeries, and arrhythmias also contribute to this. Gender, fluid balance, and RACHS-1 Scoring were not significant. While further research and testing are required for the use of midodrine. However, the low-fat formula of Monogen has proven to be an effective treatment.

[1]  V. Hjortdal,et al.  Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease , 2020, Current Cardiology Reports.

[2]  H. Park,et al.  Chylothorax after Surgery for Congenital Cardiac Disease: A Prevention and Management Protocol , 2020, The Korean journal of thoracic and cardiovascular surgery.

[3]  Adnan M. Bakar,et al.  Non-surgical Risk Factors for the Development of Chylothorax in Children after Cardiac Surgery-Does Fluid Matter? , 2019, Pediatric Cardiology.

[4]  B. Latal,et al.  Comparison of postoperative chylothorax in infants and children with trisomy 21 and without dysmorphic syndrome: Is there a difference in clinical outcome? , 2019, Journal of pediatric surgery.

[5]  W. Cai,et al.  ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Complications. , 2018, Clinical nutrition.

[6]  A. Saxena,et al.  Surgical chylothorax in neonates: management and outcomes , 2018, World Journal of Pediatrics.

[7]  A. Székely,et al.  Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis. , 2017, Journal of thoracic disease.

[8]  C. Roca,et al.  CP-071 Midodrine in refractory chylothorax after paediatric cardiac surgery , 2016 .

[9]  C. Fraser,et al.  Incidence and treatment of chylothorax after cardiac surgery in children: analysis of a large multi-institution database. , 2014, The Journal of thoracic and cardiovascular surgery.

[10]  J. Hirsch,et al.  Utility of a clinical practice guideline in treatment of chylothorax in the postoperative congenital heart patient. , 2013, The Annals of thoracic surgery.

[11]  E. Ley,et al.  Midodrine: a novel therapeutic for refractory chylothorax. , 2013, Chest.

[12]  Maria T. Zuluaga Chylothorax after surgery for congenital heart disease , 2012, Current opinion in pediatrics.

[13]  M. Ozkan,et al.  Management of chylothorax with octreotide after congenital heart surgery. , 2011, The Thoracic and cardiovascular surgeon.

[14]  J. Schulte‐Mönting,et al.  Chylothorax after surgery on congenital heart disease in newborns and infants -risk factors and efficacy of MCT-diet , 2010, Journal of cardiothoracic surgery.

[15]  M. Milonakis,et al.  Etiology and Management of Chylothorax Following Pediatric Heart Surgery , 2009, Journal of cardiac surgery.

[16]  W. Wells,et al.  Thoracic duct ligation for persistent chylothorax after pediatric cardiothoracic surgery. , 2009, The Annals of thoracic surgery.

[17]  Y. Cheung,et al.  Chylothorax in children after congenital heart surgery. , 2006, The Annals of thoracic surgery.

[18]  Thomas E. Nichols,et al.  HHS Public Access , 2018 .

[19]  C. Roca,et al.  Midodrine in refractory chylothorax after pediatric cardiac surgery: A case report , 2016 .

[20]  B. Matrot,et al.  Assessing fluid balance in critically ill pediatric patients , 2014, European Journal of Pediatrics.